Outlook Therapeutics, Inc. (OTLK) Share-based Payment Arrangement, Expense USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Outlook Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2018 to 2024.
  • Outlook Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $1.31 M, a 5.27% decline year-over-year.
  • Outlook Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $5.35 M, a 3% decline year-over-year.
  • Outlook Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $5.55 M, a 28.1% decline from 2022.
  • Outlook Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $7.71 M, a 57.8% increase from 2021.
  • Outlook Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $4.89 M, a 74.1% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $5.35 M $1.31 M -$72.9 K -5.27% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $5.43 M $1.27 M -$120 K -8.6% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-14
Q3 2023 $5.55 M $1.39 M +$13.3 K +0.97% Jul 1, 2023 Sep 30, 2023 10-K 2023-12-22
Q2 2023 $5.53 M $1.38 M +$13.9 K +1.02% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $5.52 M $1.38 M -$2.38 M -63.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 $7.9 M $1.39 M +$188 K +15.6% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 $7.71 M $1.38 M -$28.4 K -2.02% Jul 1, 2022 Sep 30, 2022 10-K 2023-12-22
Q2 2022 $7.74 M $1.37 M +$169 K +14.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $7.57 M $3.76 M +$2.63 M +233% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $4.94 M $1.2 M +$49.4 K +4.28% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-14
Q3 2021 $4.89 M $1.4 M +$620 K +79% Jul 1, 2021 Sep 30, 2021 10-K 2022-12-29
Q2 2021 $4.27 M $1.2 M -$160 K -11.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $4.43 M $1.13 M +$825 K +271% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-13
Q4 2020 $3.6 M $1.15 M +$795 K +221% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 $2.81 M $785 K +$580 K +284% Jul 1, 2020 Sep 30, 2020 10-K 2021-12-23
Q2 2020 $2.23 M $1.36 M +$1.39 M Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-13
Q1 2020 $837 K $305 K +$36.8 K +13.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-14
Q4 2019 $801 K $359 K -$513 K -58.8% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-16
Q3 2019 $1.31 M $205 K Jul 1, 2019 Sep 30, 2019 10-K 2020-12-23
Q2 2019 -$31.3 K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 $268 K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q4 2018 $872 K Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.